BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu P, Hsu C, Hsia C, Lee Y, Huang Y, Su C, Lee F, Lin H, Huo T. Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. European Journal of Cancer 2016;63:25-33. [DOI: 10.1016/j.ejca.2016.04.023] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, Huang YH, Lei HJ, He YJ, Hou MC, Huo TI. An Albumin-Bilirubin (ALBI) Grade-based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria. Am J Clin Oncol. 2019;42:698-704. [PMID: 31335351 DOI: 10.1097/coc.0000000000000581] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
2 Adhoute X, Pénaranda G, Raoul JL, Bronowicki JP, Anty R, Bourlière M. “Six-and-twelve” score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort. World J Hepatol 2020; 12(8): 525-532 [PMID: 32952879 DOI: 10.4254/wjh.v12.i8.525] [Reference Citation Analysis]
3 Chen ZH, Hong YF, Chen X, Chen J, Lin Q, Lin J, Li X, Wen JY, Ruan DY, Dong M, Wei L, Wang TT, Lin ZX, Ma XK, Wu DH, Wu XY, Xu R. Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing trans-arterial chemoembolization therapy. Oncol Lett 2018;15:855-62. [PMID: 29403561 DOI: 10.3892/ol.2017.7419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
4 Heinrich S, Sprinzl M, Schmidtmann I, Heil E, Koch S, Czauderna C, Heinrich B, Philippe P Diggs L, Wörns MA, Kloeckner R, Galle PR, Marquardt JU, Weinmann A. Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. United European Gastroenterol J 2020;8:444-52. [PMID: 32213028 DOI: 10.1177/2050640620904524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Chen X, Liao Y, Yu Y, Zhu P, Li J, Qin L, Liao W, Huang Z. Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma. Oncotarget 2017;8:92589-603. [PMID: 29190940 DOI: 10.18632/oncotarget.21506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Huo TI, Liu PH, Hsu CY. Staging and Restaging for Hepatocellular Carcinoma: Solution of Confusion? Hepatology 2019;69:464-5. [PMID: 30353930 DOI: 10.1002/hep.30324] [Reference Citation Analysis]
7 Marasco G, Trevisani F; Italian Liver Cancer (ITA.LI.CA.) group. Time to move beyond the classical prognostic systems for patients with advanced hepatocellular carcinoma undergoing Sorafenib. Dig Liver Dis 2021;53:1210-1. [PMID: 34052178 DOI: 10.1016/j.dld.2021.04.037] [Reference Citation Analysis]
8 Campani C, Vitale A, Dragoni G, Arena U, Laffi G, Cillo U, Giannini EG, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Biasini E, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Farinati F, Trevisani F, Marra F. Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Liver Cancer 2021;10:126-36. [PMID: 33977089 DOI: 10.1159/000513404] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Sang W, Chan SL, Chan AW. Comments on "Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients". Eur J Cancer 2016;68:203-5. [PMID: 27720569 DOI: 10.1016/j.ejca.2016.08.023] [Reference Citation Analysis]
10 Papaconstantinou D, Hewitt DB, Brown ZJ, Schizas D, Tsilimigras DI, Pawlik TM. Patient stratification in hepatocellular carcinoma: impact on choice of therapy. Expert Rev Anticancer Ther 2022. [PMID: 35157530 DOI: 10.1080/14737140.2022.2041415] [Reference Citation Analysis]
11 Liu PH, Huo TI. Utility of prognostic scoring systems in management of hepatocellular carcinoma. Eur J Cancer. 2016;68:206-207. [PMID: 27697407 DOI: 10.1016/j.ejca.2016.08.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Huo TI, Ho SY, Liu PH. Selecting an optimal prognostic model for advanced hepatocellular carcinoma: Any new ideas? Dig Liver Dis 2021;53:1208-9. [PMID: 34011481 DOI: 10.1016/j.dld.2021.04.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Bednarsch J, Czigany Z, Heise D, Joechle K, Luedde T, Heij L, Bruners P, Ulmer TF, Neumann UP, Lang SA. Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems. Langenbecks Arch Surg. 2021;406:75-86. [PMID: 33294952 DOI: 10.1007/s00423-020-02052-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Shen J, He L, Li C, Wen T, Chen W, Lu C, Yan L, Li B, Yang J. Prognostic nomograms for patients with resectable hepatocelluar carcinoma incorporating systemic inflammation and tumor characteristics. Oncotarget 2016;7:80783-93. [PMID: 27811374 DOI: 10.18632/oncotarget.13038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
15 Swersky A, Kulik L, Kalyan A, Grace K, Caicedo JC, Lewandowski RJ, Salem R. Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach. Semin Intervent Radiol 2021;38:432-7. [PMID: 34629710 DOI: 10.1055/s-0041-1735528] [Reference Citation Analysis]
16 Huo TI, Liu PH, Hsu CY. Letter to the Editor: Using Circulating Biomarkers to Stage HCC: Pitfalls and Limitations. Hepatology 2021;73:2611. [PMID: 33170973 DOI: 10.1002/hep.31618] [Reference Citation Analysis]
17 Lin Z, Cai Y, Chen R, Chen B, Zhao L, Xu S, Wang X, Song M, Wu J, Wang Y, Zhou M, Shi K. A microRNA expression profile for vascular invasion can predict overall survival in hepatocellular carcinoma. Clinica Chimica Acta 2017;469:171-9. [DOI: 10.1016/j.cca.2017.03.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
18 Hsu CY, Liu PH, Hsia CY, Lee YH, Nagaria TS, Lee RC, Ho SY, Hou MC, Huo TI. A New Treatment-integrated Prognostic Nomogram of the Barcelona Clinic Liver Cancer System for Hepatocellular Carcinoma. Sci Rep 2017;7:7914. [PMID: 28801646 DOI: 10.1038/s41598-017-08382-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
19 Ridder DA, Schindeldecker M, Weinmann A, Berndt K, Urbansky L, Witzel HR, Heinrich S, Roth W, Straub BK. Key Enzymes in Pyrimidine Synthesis, CAD and CPS1, Predict Prognosis in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:744. [PMID: 33670206 DOI: 10.3390/cancers13040744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Masotto A, Trevisani F. A Liver Index and its Relationship to Indices of HCC Aggressiveness. J Integr Oncol 2016;5:178. [PMID: 28580457 DOI: 10.4172/2329-6771.1000178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
21 Ho SY, Liu PH, Hsu CY, Hsia CY, Lee YH, Lee RC, Huang YH, Lee FY, Hou MC, Tsai YJ, Huo TI. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS One. 2017;12:e0180408. [PMID: 28672011 DOI: 10.1371/journal.pone.0180408] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
22 Huo TI, Liao JI, Ho SY. Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet? J Hepatol 2021:S0168-8278(21)02176-0. [PMID: 34780876 DOI: 10.1016/j.jhep.2021.11.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Zhong JH, Torzilli G, Xing H, Li C, Han J, Liang L, Zhang H, Dai SY, Li LQ, Shen F, Yang T. Controversies and evidence of hepatic resection for hepatocellular carcinoma. BBA Clin. 2016;6:125-130. [PMID: 27761414 DOI: 10.1016/j.bbacli.2016.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
24 Zhang X, El-Serag HB, Thrift AP. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes Control 2021;32:317-25. [PMID: 33394207 DOI: 10.1007/s10552-020-01386-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhang XP, Gao YZ, Jiang YB, Wang K, Chen ZH, Guo WX, Shi J, Zhang YJ, Chen MS, Lau WY, Cheng SQ. A serological scoring system to predict lymph node metastasis in patients with hepatocellular carcinoma. HPB (Oxford) 2019;21:335-44. [PMID: 30104175 DOI: 10.1016/j.hpb.2018.07.013] [Reference Citation Analysis]
26 Vitale A, Farinati F, Finotti M, Di Renzo C, Brancaccio G, Piscaglia F, Cabibbo G, Caturelli E, Missale G, Marra F, Sacco R, Giannini EG, Trevisani F, Cillo U, Associazione Italiana Per Lo Studio Del Fegato Aisf Hcc Special Interest Group, Italian Liver Cancer Ita Li Ca Study Group. Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers (Basel) 2021;13:1673. [PMID: 33918125 DOI: 10.3390/cancers13071673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Campigotto M, Giuffrè M, Colombo A, Visintin A, Aversano A, Budel M, Masutti F, Abazia C, Crocé LS. Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature. World J Hepatol 2020; 12(12): 1239-1257 [PMID: 33442451 DOI: 10.4254/wjh.v12.i12.1239] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
28 Zhong JH, Peng NF, You XM, Ma L, Xiang X, Wang YY, Gong WF, Wu FX, Xiang BD, Li LQ. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study. Oncotarget 2017;8:18296-302. [PMID: 28407686 DOI: 10.18632/oncotarget.15433] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
29 Zhang R, Chen J, Jiang Y, Wang J, Chen S. Prognostic nomogram for hepatocellular carcinoma with fibrosis of varying degrees: a retrospective cohort study. Ann Transl Med 2020;8:1429. [PMID: 33313174 DOI: 10.21037/atm-20-3267] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Demirtas CO, Ricco G, Ozdogan OC, Baltacioglu F, Ones T, Yumuk PF, Dulundu E, Uzun S, Colombatto P, Oliveri F, Brunetto MR, Gunduz F. Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders. Hepatol Commun 2021. [PMID: 34751001 DOI: 10.1002/hep4.1836] [Reference Citation Analysis]
31 Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort. World J Gastroenterol 2017; 23(14): 2545-2555 [PMID: 28465639 DOI: 10.3748/wjg.v23.i14.2545] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
32 Chen P, Chiu N, Su C, Huang Y, Hou M, Lin H, Wu J. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. Journal of the Chinese Medical Association 2019;82:2-10. [DOI: 10.1097/jcma.0000000000000001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]